FI3546462T3 - Uusi oksoisokinoliinijohdannainen - Google Patents
Uusi oksoisokinoliinijohdannainen Download PDFInfo
- Publication number
- FI3546462T3 FI3546462T3 FIEP17874560.0T FI17874560T FI3546462T3 FI 3546462 T3 FI3546462 T3 FI 3546462T3 FI 17874560 T FI17874560 T FI 17874560T FI 3546462 T3 FI3546462 T3 FI 3546462T3
- Authority
- FI
- Finland
- Prior art keywords
- group
- pharmaceutically acceptable
- acceptable salt
- disease
- optionally substituted
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 claims 9
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- -1 morpholinoacetyl group Chemical group 0.000 claims 3
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 2
- 102000001714 Agammaglobulinaemia Tyrosine Kinase Human genes 0.000 claims 2
- 108010029445 Agammaglobulinaemia Tyrosine Kinase Proteins 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 206010005949 Bone cancer Diseases 0.000 claims 2
- 208000020084 Bone disease Diseases 0.000 claims 2
- 208000018084 Bone neoplasm Diseases 0.000 claims 2
- 230000002159 abnormal effect Effects 0.000 claims 2
- 230000036755 cellular response Effects 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 125000003566 oxetanyl group Chemical group 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- 125000004853 tetrahydropyridinyl group Chemical group N1(CCCC=C1)* 0.000 claims 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 125000003107 substituted aryl group Chemical group 0.000 claims 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 1
- 125000005942 tetrahydropyridyl group Chemical group 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Claims (12)
1. Oksoisokinoliinijohdannainen, kaavalla (I): Rp pe ai \/ (D jossa R! on valinnaisesti substituoitu C1-3-alkyyli, O on rakenne (a): PÄ LÄ NH, (a) — jossa R? ja R? ovat itsenäisesti vetyatomi, valinnaisesti substituoitu C1-3-alkyyliryhmä, valinnaisesti substituoitu sykloalkyyliryhmä, valinnaisesti substituoitu aryyliryhma, valinnaisesti substituoitu heteroaryyliryhmä tai valinnaisesti substituoitu heterosykli- nen ryhmä, tai niiden farmaseuttisesti hyväksyttävä suola.
2. Patenttivaatimuksen 1 mukainen oksoisokinoliinijohdannainen, jossa R! on hyd- roksimetyyliryhmä tai sen farmaseuttisesti hyväksyttävä suola.
3. Patenttivaatimuksen 1, kaavan (la) mukainen oksoisokinoliinijohdannainen: pei A LLL NH N i = Ng JII L Ola) — jossa R? on valinnaisesti substituoitu tetrahydropyridyyliryhmä, tai sen farmaseutti- sesti hyväksyttävä suola.
4. Patenttivaatimuksen 3 mukainen oksoisokinoliinijohdannainen, tunnettu siitä, että tetrahydropyridiiniryhmän substituentti on valittu ryhmästä, jonka muodostavat ok- setanyyliryhmä, asetyyliryhmä, propionyyliryhmä, morfolinoasetyyliryhmä, dimetyy- likarbamoyyliryhmä, pyrrolidiinikarbonyyliryhmä, metyylisulfonyyliryhmä. ryhmä ja —isopropyylisulfonyyliryhmä tai niiden farmaseuttisesti hyväksyttävä suola.
5. Patenttivaatimuksen 3 mukainen oksoisokinoliinijohdannainen, tunnettu siitä, että tetrahydropyridiiniryhmän substituentti on oksetanyyliryhmä, tai sen farmaseuttisesti hyväksyttävä suola.
6. Farmaseuttinen koostumus, joka sisältää jonkin patenttivaatimuksen 1-5 mukais- ta oksoisokinoliinijohdannaista tai sen farmaseuttisesti hyväksyttävää suolaa.
7. Jonkin patenttivaatimuksen 1-5 mukainen oksoisokinoliinijohdannainen tai sen —farmaseuttisesti hyväksyttävä suola käytettäväksi lääkkeenä.
8. Jonkin patenttivaatimuksen 1-5 mukainen oksoisokinoliinijohdannainen tai sen farmaseuttisesti hyväksyttävä suola käytettäväksi sellaisen sairauden ehkäisyssä tai hoidossa, joka liittyy Brutonin tyrosiinikinaasin aiheuttamaan epänormaaliin soluvas- — teeseen.
9. Oksoisokinoliinijohdannainen tai sen farmaseuttisesti hyväksyttävä suola käytet- täväksi patenttivaatimuksen 8 mukaisesti, tunnettu siitä, että sairaus on autoim- muunisairaus, tulehdussairaus, luusairaus tai syöpä.
10. Patenttivaatimuksen 6 mukainen farmaseuttinen koostumus käytettäväksi lääk- keenä.
11. Patenttivaatimuksen 6 mukainen farmaseuttinen koostumus käytettäväksi sellai- sen sairauden ehkäisyyn tai hoitoon, joka liittyy Brutonin tyrosiinikinaasin aiheutta- maan epänormaaliin soluvasteeseen.
12. Farmaseuttinen koostumus käytettäväksi patenttivaatimuksen 11 mukaisesti, tunnettu siitä, että sairaus on autoimmuunisairaus, tulehdussairaus, luusairaus tai syöpä.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2016229262 | 2016-11-25 | ||
| JP2017191488 | 2017-09-29 | ||
| PCT/JP2017/042172 WO2018097234A1 (ja) | 2016-11-25 | 2017-11-24 | 新規オキソイソキノリン誘導体 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI3546462T3 true FI3546462T3 (fi) | 2024-01-11 |
Family
ID=62195030
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP17874560.0T FI3546462T3 (fi) | 2016-11-25 | 2017-11-24 | Uusi oksoisokinoliinijohdannainen |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US10793575B2 (fi) |
| EP (1) | EP3546462B1 (fi) |
| JP (1) | JP7015060B2 (fi) |
| KR (1) | KR102565546B1 (fi) |
| CN (1) | CN109963852B (fi) |
| AU (1) | AU2017364720B2 (fi) |
| BR (1) | BR112019010617A2 (fi) |
| CA (1) | CA3044933A1 (fi) |
| DK (1) | DK3546462T3 (fi) |
| ES (1) | ES2968023T3 (fi) |
| FI (1) | FI3546462T3 (fi) |
| MX (1) | MX2019006079A (fi) |
| WO (1) | WO2018097234A1 (fi) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20230100235A1 (en) * | 2020-02-05 | 2023-03-30 | Carna Biosciences, Inc. | Anticancer agent composition |
| JPWO2022102715A1 (fi) * | 2020-11-13 | 2022-05-19 | ||
| WO2022140246A1 (en) | 2020-12-21 | 2022-06-30 | Hangzhou Jijing Pharmaceutical Technology Limited | Methods and compounds for targeted autophagy |
| CA3241069A1 (en) | 2021-12-14 | 2023-06-22 | Adrianus Petrus Antonius De Man | Macrocyclic btk inhibitors |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013133367A1 (ja) | 2012-03-09 | 2013-09-12 | カルナバイオサイエンス株式会社 | 新規トリアジン誘導体 |
| WO2013157021A1 (en) * | 2012-04-20 | 2013-10-24 | Advinus Therapeutics Limited | Bicyclic compounds, compositions and medicinal applications thereof |
| EP2838898B1 (en) * | 2012-04-20 | 2017-01-18 | Advinus Therapeutics Limited | Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof |
| CN104211703B (zh) | 2013-05-30 | 2018-04-03 | 南京勇山生物科技有限公司 | 一类作为布鲁顿激酶抑制剂的稠杂环化合物 |
| EP3026050B1 (en) | 2013-07-26 | 2018-11-07 | Carna Biosciences Inc. | Novel triazine derivative |
| US20160221991A1 (en) * | 2013-09-20 | 2016-08-04 | Carna Biosciences, Inc. | Novel triazine derivative |
-
2017
- 2017-11-24 DK DK17874560.0T patent/DK3546462T3/da active
- 2017-11-24 FI FIEP17874560.0T patent/FI3546462T3/fi active
- 2017-11-24 AU AU2017364720A patent/AU2017364720B2/en active Active
- 2017-11-24 ES ES17874560T patent/ES2968023T3/es active Active
- 2017-11-24 US US16/463,493 patent/US10793575B2/en active Active
- 2017-11-24 CN CN201780072975.7A patent/CN109963852B/zh active Active
- 2017-11-24 KR KR1020197018178A patent/KR102565546B1/ko active IP Right Grant
- 2017-11-24 MX MX2019006079A patent/MX2019006079A/es unknown
- 2017-11-24 JP JP2018552969A patent/JP7015060B2/ja active Active
- 2017-11-24 WO PCT/JP2017/042172 patent/WO2018097234A1/ja unknown
- 2017-11-24 CA CA3044933A patent/CA3044933A1/en active Pending
- 2017-11-24 BR BR112019010617A patent/BR112019010617A2/pt active Search and Examination
- 2017-11-24 EP EP17874560.0A patent/EP3546462B1/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| DK3546462T3 (da) | 2024-03-04 |
| WO2018097234A1 (ja) | 2018-05-31 |
| BR112019010617A2 (pt) | 2019-09-17 |
| EP3546462A1 (en) | 2019-10-02 |
| AU2017364720A1 (en) | 2019-06-20 |
| MX2019006079A (es) | 2019-11-12 |
| JPWO2018097234A1 (ja) | 2019-10-17 |
| RU2019119374A3 (fi) | 2020-12-25 |
| CN109963852A (zh) | 2019-07-02 |
| EP3546462B1 (en) | 2024-01-03 |
| CA3044933A1 (en) | 2018-05-31 |
| KR102565546B1 (ko) | 2023-08-10 |
| AU2017364720B2 (en) | 2021-09-23 |
| KR20190104142A (ko) | 2019-09-06 |
| RU2019119374A (ru) | 2020-12-25 |
| JP7015060B2 (ja) | 2022-02-02 |
| US10793575B2 (en) | 2020-10-06 |
| ES2968023T3 (es) | 2024-05-06 |
| EP3546462A4 (en) | 2020-07-01 |
| CN109963852B (zh) | 2021-12-03 |
| US20190359616A1 (en) | 2019-11-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI3546462T3 (fi) | Uusi oksoisokinoliinijohdannainen | |
| CY1123994T1 (el) | Δικυκλικες-συντηγμενες ενωσεις ετεροαρυλιου ή αρυλιου ως ρυθμιστες της irak4 | |
| WO2017205536A3 (en) | Heterocyclic inhibitors of cbp/ep300 and their use in the treatment of cancer | |
| PH12020551305A1 (en) | Pharmaceutical Compounds | |
| CY1120248T1 (el) | Ενωσεις ιμιδαζο[4,5-c]κινολιν-2-ονης και η χρηση τους στη θεραπευτικη αντιμετωπιση του καρκινου | |
| PH12020500125A1 (en) | 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | |
| EA201992126A1 (ru) | Ингибиторы jak, содержащие 4-членный гетероциклический амид | |
| PH12020552004A1 (en) | Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof | |
| WO2018155916A3 (ko) | 피롤로-피리미딘 유도체 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 단백질 키나아제 관련 질환의 예방 또는 치료용 약학적 조성물 | |
| MA31571B1 (fr) | Composes organiques | |
| MY192521A (en) | Bicyclic-fused heteroaryl or aryl compounds and their use as irak4 inhibitors | |
| BRPI0408068A (pt) | derivados de 5-feniltiazol e seus usos como inibidores de pi3 cinase | |
| NO341617B1 (no) | Dihydropyrazolpyrimidinonderivater, deres anvendelse i terapi og til behandling av kreft, deres anvendelse for fremstilling av et medikament, og for anvendelse som strålingssensibilisator, farmasøytisk sammensetning derav, samt et kombinert preparat for administrering ved behandling av kreft. | |
| EA201001126A1 (ru) | Пирролопиримидины и пирролопиридины | |
| WO2006067445A3 (en) | Csf-1r kinase inhibitors | |
| WO2009155121A3 (en) | Inhibitors of pi3 kinase | |
| EA201000615A1 (ru) | Производные имидазо[1,2-а]пиридина, применимые в качестве ингибиторов апк (активиноподобной киназы) | |
| CL2008001230A1 (es) | Compuestos derivados de pirrol (2.3-d)pirimidina. purin-6-ilo o pirazol(3,4-d)pirimldina, inhibidores de quinasa p70 s6; composición farmaceutica; y uso para la preparación de medicamentos utiles en el tratamiento de adenocarcinomas del colon e inhibición de angiogénesis. | |
| BRPI0810641A2 (pt) | "compostos farmacêuticos". | |
| CL2020000363A1 (es) | Inhibidores macrocíclicos de mcl-1 y métodos de uso. | |
| EA201001687A1 (ru) | Производные имидазопиридина в качестве ингибиторов активиноподобной рецепторной киназы ( alk-4 или alk-5 ) | |
| EA200701780A1 (ru) | Противоопухолевое средство | |
| TN2019000204A1 (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| EA202192900A1 (ru) | Модуляторы пути интегрированной реакции на стресс | |
| EA201990902A1 (ru) | Ингибиторы тирозинкиназы брутона |